Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aronsson, A.
Right arrow Articles by Gemzell-Danielsson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aronsson, A.
Right arrow Articles by Gemzell-Danielsson, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 19, No. 1, 81-84, January 2004
© 2004 European Society of Human Reproduction and Embryology

Effects of misoprostol on uterine contractility following different routes of administration

A. Aronsson, M. Bygdeman and K. Gemzell-Danielsson1

Department of Woman and Child Health, Division for Obstetrics and Gynaecology, Karolinska Institute/Hospital, S-171 76 Stockholm, Sweden

1 To whom correspondence should be addressed. e-mail: kristina.gemzell@kbh.ki.se

BACKGROUND: The effect of misoprostol administered by different routes on pregnant uterine contractility was investigated. METHODS: Thirty-two women with a pregnancy between 8 and 11 weeks of gestation requesting termination of pregnancy were recruited. Misoprostol was administered either orally (0.4 mg), vaginally (0.4 mg) or sublingually (0.2 or 0.4 mg) according to consecutive allocation. Intrauterine pressure was recorded using a Grass polygraph connected to a pressure transducer 30 min before misoprostol was given and for 4 h thereafter. At the end of the recording, suction curettage was performed. RESULTS: The first effect observed was an increase in uterine tonus, which occurred after a significantly shorter time following oral (7.8 min) and sublingual (10.7– 11.5 min) than after vaginal (19.4 min) treatment. The time to maximum tonus elevation was also significantly shorter (39.5, 47.1–51.7 and 62.2 min for the three groups respectively). Regular uterine contractions developed in all subjects following sublingual and vaginal administration but not after oral administration. The increase in uterine activity measured in Montevideo Units was significantly higher after 2 h and thereafter for sublingual and vaginal treatment than for oral misoprostol. CONCLUSIONS: Based on recording of uterine activity, sublingual misoprostol acts as rapidly as oral treatment, while development of contractions was similar to that seen following vaginal administration.

Key words: misoprostol/pregnancy/sublingual administration/uterine contractility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
O. S. Tang, H. Schweer, S. W.H. Lee, and P. C. Ho
Pharmacokinetics of repeated doses of misoprostol
Hum. Reprod., August 1, 2009; 24(8): 1862 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. von Hertzen, G. Piaggio, D. Wojdyla, N. T. M. Huong, L. Marions, G. Okoev, A. Khomassuridze, A. Kereszturi, S. Mittal, R. Nair, et al.
Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial
Hum. Reprod., January 1, 2009; 24(1): 106 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. Saav, A. Aronsson, L. Marions, O. Stephansson, and K. Gemzell-Danielsson
Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial
Hum. Reprod., October 1, 2007; 22(10): 2647 - 2652.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Aronsson, C. Fiala, O. Stephansson, F. Granath, B. Watzer, H. Schweer, and K. Gemzell-Danielsson
Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol
Hum. Reprod., July 1, 2007; 22(7): 1912 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
S. Lalitkumar, M. Bygdeman, and K. Gemzell-Danielsson
Mid-trimester induced abortion: a review
Hum. Reprod. Update, January 1, 2007; 13(1): 37 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Fiala, A. Aronsson, F. Granath, O. Stephansson, H.W. Seyberth, B. Watzer, and K. Gemzell-Danielsson
Pharmacokinetics of a novel oral slow-release form of misoprostol
Hum. Reprod., December 1, 2005; 20(12): 3414 - 3418.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Fiala, A. Aronsson, O. Stephansson, and K. Gemzell-Danielsson
Effects of slow release misoprostol on uterine contractility in early pregnancy
Hum. Reprod., September 1, 2005; 20(9): 2648 - 2652.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. Hamoda, P. W. Ashok, G. M.M. Flett, and A. Templeton
A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation
Hum. Reprod., August 1, 2005; 20(8): 2348 - 2354.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.